Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166408 | 0.92 | CYP3A4 (0.44) | CYP3A4ACEMEN1KMT2AUSP2 | |
| SCHEMBL4800041 | 0.89 | ACE (0.47) | CYP3A4ACEMEN1KMT2AUSP2 | |
| SCHEMBL4799220 | 0.87 | CYP3A4 (0.44) | CYP3A4ACEMEN1KMT2AUSP2 | |
| SCHEMBL4798929 | 0.87 | CYP3A4 (0.53) | CYP3A4KMT2AGRIN2BSMN1; SMN2PKM | |
| SCHEMBL4800605 | 0.86 | CACNA1B (0.45) | CYP3A4ACEMEN1KMT2AUSP2 | |
| SCHEMBL4796498 | 0.86 | HTR2A (0.38) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4799891 | 0.85 | CYP3A4 (0.43) | CYP3A4ACEGRIN2BSMN1; SMN2PKM | |
| SCHEMBL4796575 | 0.84 | FKBP1A (0.44) | CYP3A4GRIN2BSMN1; SMN2PKMHTT | |
| SCHEMBL4798199 | 0.84 | ACE (0.46) | CYP3A4ACEMEN1KMT2AUSP2 | |
| SCHEMBL4796044 | 0.83 | CYP3A4 (0.45) | CYP3A4GRIN2BSMN1; SMN2PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439036-B2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | IDO1, IDO2, APEH | CYP3A4 365/4885ACE 1148/4885MEN1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.